Tagged with S

USA US healthcare is often seen as a fragmented system of contrasts. The country has the highest healthcare expenditures as a percentage of GDP and the highest drug prices in the OECD, supporting the largest and most innovative healthcare market globally. However, it also has shockingly subpar healthcare outcomes compared to…

Spain PharmaMar, a Spanish firm, is beginning Phase II clinical trials for its anti-tumour drug Aplidin to treat coronavirus. The firm’s stocks have soared on the news.   PharmaMar is joining the race to find a treatment for COVID1-9. The Madrid-based company that developed multiple myeloma therapy Aplidin (plitidepsin) announced that…

Morocco Mohamed El Bouhmadi, president and CEO of Zenith Pharma, walks us through the company’s evolution since we last met in 2015. He shares his strategy to position the company as the Moroccan champion in Africa through in-house product development and production as well as implementing an export strategy in close…

Belgium Sabena Solomon, general manager of GSK Benelux, speaks about her first impressions of the Belgium market, having come from GSK Finland, and her initial priorities for leading the affiliate. Solomon goes on to explain GSK’s continued commitment to ensuring patients have access to innovative medicines, the role the company plays…

UAE Neil McMaster, GAC Dubai’s General Manager Contract Logistics, discusses the key investments his company has made to stand out as the region’s go-to healthcare and pharmaceutical logistics provider, offering added-value services and high-quality customer standards. He also introduces GAC Dubai’s new high-tech building facility, reveals the key trends and challenges…

Belgium Karel Van De Sompel, country manager of Pfizer in Belgium and Luxembourg and chairman of Pharma.be, highlights the key changes he sees in today’s pharma market which revolve around the increasing trend of personalized medicine, digitalization, big healthcare data, and stakeholder partnerships. Additionally, Van De Sompel also elaborates on Pfizer’s…

Belgium On 16 April 2020, a new Act was adopted by the Belgian parliament to increase the transparency of managed entry agreements (‘MEA’) concluded between pharmaceutical companies and the National Institute for Health and Disability Insurance (‘NIHDI’). MEAs stipulate confidential compensation mechanisms for the Belgian government regarding the publicly-listed price and reimbursement…

Coronavirus Takeda’s Head of R&D Patient Engagement Jessica Scott examines the parallels between partnering with patients and working remotely with colleagues in the time of COVID-19.   Patients need us to engage with them, ask questions and listen. Just as we’re experiencing now with our own work relationships with colleagues, deeper…

USA Marc Boutin, JD, CEO of the National Health Council (NHC),* introduces the organization and its mission to provide a united voice for the 160 million people in the US living with chronic diseases and disabilities and their family caregivers. He addresses the challenge faced by patients living with chronic diseases…

Cell & Gene Therapy Two years on from the introduction of Novartis Oncology’s CAR-T therapy to Europe, Emnuele Ostuni, the firm’s European head of cell and gene therapy, spoke to PharmaBoardroom about the pioneering product’s journey to market, what has been learnt along the way, and how his team has worked to assuage concerns…

Cell & Gene Therapy Emanuele Ostuni, Novartis Oncology’s head of cell and gene therapy for Europe, gives an overview of the introduction of the company’s CAR-T therapy to Europe, the work still to be done to get this product to more patients who need it across the continent, and the future of cell and…

China I-Mab Biopharma CFO Jielun Zhu recaps the exciting milestones for the company over the past year since our last interview in May 2019, including most notably their NASDAQ IPO in January 2020, as well as shares some insights on the NASDAQ IPO experience.   Before the IPO, we might have…